

# Alex C Spyropoulos

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3916166/alex-c-spyropoulos-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150 papers	12,404 citations	43 h-index	111 g-index
163 ext. papers	15,274 ext. citations	7.4 avg, IF	6.35 L-index

#	Paper	IF	Citations
150	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , <b>2014</b> , 35, 3033-69, 3069a-3069k	9.5	1974
149	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2950-2973	15.1	1682
148	Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e326S-e350S	5.3	1175
147	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 823-33	59.2	719
146	The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 299S-339S	5.3	621
145	Rivaroxaban for thromboprophylaxis in acutely ill medical patients. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 513-23	59.2	424
144	Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. <i>Chest</i> , <b>2007</b> , 132, 936-45	5.3	377
143	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1859-1865	15.4	367
142	Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. <i>Circulation</i> , <b>2012</b> , 126, 1630-9	16.7	322
141	Predictive and associative models to identify hospitalized medical patients at risk for VTE. <i>Chest</i> , <b>2011</b> , 140, 706-714	5.3	278
140	How I treat anticoagulated patients undergoing an elective procedure or surgery. <i>Blood</i> , <b>2012</b> , 120, 2954-62	4.62	265
139	Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. <i>Chest</i> , <b>2011</b> , 139, 69-79	5.3	253
138	Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). <i>Circulation</i> , <b>2014</b> , 130, 1876-83	16.7	188
137	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 625-32	7	158
136	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , <b>2019</b> , 179, 1469-1478	11.5	156
135	Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 750-9	7	156
134	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1004-1024	7	147

133	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1118-1127	59.2	143
132	Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 291-302	7	114
131	Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. <i>Chest</i> , <b>2002</b> , 122, 108-145	5.3	103
130	A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. <i>Oncologist</i> , <b>2017</b> , 22, 1222-1231	5.7	99
129	Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. <i>Chest</i> , <b>2004</b> , 125, 1642-50	5.3	92
128	Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 407-16	5.1	84
127	External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e001152	6	83
126	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1612-1620	11.5	81
125	Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. <i>TH Open</i> , <b>2020</b> , 4, e59-e65	2.7	74
124	Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 883-9	3	73
123	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1597-1628	7	73
122	Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2958-2967	15.4	69
121	Direct oral anticoagulants: new drugs and new concepts. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 1333-51	5	67
120	Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 1149-59	3.5	63
119	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , <b>2017</b> , 1, e56-e65	2.7	62
118	Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. <i>Blood</i> , <b>2021</b> , 137, 2838-2847	2.2	59
117	Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 405-15	7	56
116	External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 692-9	7	54

115	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 1240-8	7	52
114	Rates of venous thromboembolism occurrence in medical patients among the insured population. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 102, 951-7	7	51
113	Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. <i>Chest</i> , <b>2005</b> , 128, 958-69	5.3	48
112	Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 1001.e9-1001.e18	2.4	48
111	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 2415-2424	7	45
110	Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 28, 458-64	5.1	45
109	European Union-28: An annualised cost-of-illness model for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 800-8	7	45
108	Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. <i>American Heart Journal</i> , <b>2019</b> , 212, 113-119	4.9	45
107	Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease. <i>American Journal of Medicine</i> , <b>2008</b> , 121, 935-42	2.4	42
106	Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 1109-22	2.5	41
105	Emergence of institutional antithrombotic protocols for coronavirus 2019. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 510-517	5.1	37
104	Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. <i>Circulation</i> , <b>2014</b> , 130, 410-8	16.7	37
103	Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. <i>Thrombosis Research</i> , <b>2013</b> , 132, 520-6	8.2	37
102	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , <b>2016</b> , 20, 115	10.8	35
101	New paradigms in venous thromboprophylaxis of medically ill patients. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1662-1670	7	34
100	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.. <i>Lancet, The</i> , <b>2021</b> ,	40	34
99	Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. <i>Blood</i> , <b>2020</b> , 135, 1788-1810	2.2	33
98	Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1457-64	3	33

97	Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619886022	3.3	32
96	Investigational treatments of venous thromboembolism. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 431-40	5.9	30
95	Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. <i>Thrombosis Research</i> , <b>2019</b> , 182, 159-166	8.2	29
94	Hospital-based use of thromboprophylaxis in patients with COVID-19. <i>Lancet, The</i> , <b>2020</b> , 395, e75	4.0	29
93	Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1966-1972	15.4	29
92	The use of weighted and scored risk assessment models for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1072-6	7	29
91	External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 530-6	7	28
90	Practical issues, limitations, and periprocedural management of the NOACs. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 36, 212-22	5.1	25
89	Prevention of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2006</b> , 32, 755-66	5.3	25
88	Management of venous thromboembolism in the elderly. <i>Drugs and Aging</i> , <b>2006</b> , 23, 651-71	4.7	25
87	Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 1027-34	7	24
86	Bridging therapy and oral anticoagulation: current and future prospects. <i>Current Opinion in Hematology</i> , <b>2010</b> , 17, 444-9	3.3	24
85	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 3140-3147	15.1	23
84	Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. <i>Annals of Surgery</i> , <b>2009</b> , 250, 219-28	7.8	23
83	Treatment of bleeding complications when using oral anticoagulants for prevention of strokes. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2013</b> , 15, 288-98	2.1	21
82	Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1043-1053	7	21
81	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1228-35	7	20
80	Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 544-53	7	20

79	Pro: "Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery". <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 213-6	7	19
78	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. <i>Annals of Emergency Medicine</i> , <b>2020</b> , 76, 470-485	2.1	18
77	The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 196-208	5.1	17
76	Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619850897	3.3	14
75	Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 575-582	3.3	14
74	Risk assessment of venous thromboembolism in hospitalized medical patients. <i>Current Opinion in Pulmonary Medicine</i> , <b>2010</b> , 16, 419-25	3	14
73	Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 897-901	5.1	14
72	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , <b>2021</b> , 235, 12-23	4.9	14
71	Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Circulation</i> , <b>2018</b> , 138, 1402-1411	16.7	14
70	Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019459	6	13
69	Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2019</b> , 184, 58-61	8.2	13
68	Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, 296-300	5.1	13
67	To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2010</b> , 29, 192-8	5.1	12
66	Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review. <i>Hematology/Oncology Clinics of North America</i> , <b>2016</b> , 30, 1073-84	3.1	12
65	Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 515-524	7	11
64	External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model. <i>Oncologist</i> , <b>2020</b> , 25, e1083-e1090	5.7	11
63	The management of venous thromboembolism in hospitalized patients with COVID-19. <i>Blood Advances</i> , <b>2020</b> , 4, 4028	7.8	11
62	Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 113-24	2.9	10



61	Comparison of international societal guidelines for the diagnosis of suspected pulmonary embolism during pregnancy. <i>Lancet Haematology</i> , <b>2020</b> , 7, e247-e258	14.6	10
60	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. <i>International Journal of Hematology</i> , <b>2021</b> , 113, 330-336	2.3	10
59	Medically Ill hospitalized Patients for COVID-19 THrombosis Extended Prophylaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. <i>American Heart Journal</i> , <b>2021</b> , 242, 115-122	4.9	10
58	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. <i>American Journal of Medicine</i> , <b>2016</b> , 129, S54-S63	2.4	9
57	Direct oral anticoagulants in the treatment of pulmonary embolism. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 131-140	2.5	9
56	Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2013</b> , 19, 504-12	3.3	8
55	Sex-Based Differences in COVID-19 Outcomes. <i>Journal of Women's Health</i> , <b>2021</b> , 30, 492-501	3	8
54	Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2017</b> , 23, 532-541	3.3	7
53	Cost-of-illness model for venous thromboembolism. <i>Thrombosis Research</i> , <b>2016</b> , 145, 130-2	8.2	7
52	Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis.. <i>Thrombosis Research</i> , <b>2022</b> , 209, 94-98	8.2	7
51	New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	7
50	Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis. <i>Hospital Practice (1995)</i> , <b>2018</b> , 46, 5-15	2.2	7
49	Venous thromboembolism management: where do novel anticoagulants fit?. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 783-90	2.5	6
48	Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , <b>2020</b> , 4, 3520-3527	7.8	6
47	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 992-1007	7	6
46	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 924-936	7	5
45	Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 316-320	5.1	5
44	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017316	6	5

43	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1684-1695	7.95	5
42	Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 813-822	5.3	5
41	Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3256-3262	4	4
40	Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 562-568	5.1	4
39	Studying the coagulopathy of COVID-19. <i>Lancet, The</i> , <b>2021</b> ,	4.0	4
38	External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 1032-1035	5.1	4
37	Preventing VTE in Outpatients With Cancer. <i>Chest</i> , <b>2012</b> , 142, 265-266	5.3	3
36	Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis. <i>JMIR MHealth and UHealth</i> , <b>2018</b> , 6, e11090	5.5	3
35	Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12520	5.1	3
34	Treatment and long-term management of venous thromboembolism. <i>Clinics in Laboratory Medicine</i> , <b>2014</b> , 34, 519-36	2.1	2
33	All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 685-94	7	2
32	Response. <i>Chest</i> , <b>2013</b> , 144, 1424-1426	5.3	2
31	Thromboembolic Outcomes of Hospitalized COVID-19 Patients in the 90-Day Post-Discharge Period: Early Data from the Northwell CORE-19 Registry. <i>Blood</i> , <b>2020</b> , 136, 33-34	2.2	2
30	The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer. <i>Blood</i> , <b>2011</b> , 118, 542-542	2.2	2
29	External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18005-e18005	2.2	2
28	A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, 159-167	5.1	2
27	The underrecognized prothrombotic vascular disease of COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 942-943	5.1	2
26	Prognostic Value of Venous Thromboembolism Risk Assessment Models in Patients with Severe COVID-19. <i>TH Open</i> , <b>2021</b> , 5, e211-e219	2.7	2



25	The BRIDGE trial: What the hospitalist should know. <i>Journal of Hospital Medicine</i> , <b>2016</b> , 11, 652-7	2.7	2
24	Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2021</b> , 42, 308-315	3.9	2
23	Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 570-579	5.1	1
22	Venous thromboembolism risk in patients with inflammatory bowel disease: defining the benefits of pharmacologic prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1577	6.9	1
21	Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. <i>Blood</i> , <b>2011</b> , 118, 545-545	2.2	1
20	Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated with Different Outcomes Among Patients with Venous Thromboembolism?. <i>Blood</i> , <b>2015</b> , 126, 1126-1126	2.2	1
19	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> ,	15.4	1
18	Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021579	6	1
17	Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2021</b> , 27, 10760296211053316	3.3	1
16	Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620925910	3.3	1
15	Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factors. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12547	5.1	1
14	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. <i>American Journal of Emergency Medicine</i> , <b>2016</b> , 34, 19-25	2.9	1
13	Heparin Bridging Therapy for Patients on Chronic Oral Anticoagulants in Periprocedural Settings. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2020</b> , 46, 26-31	5.3	0
12	Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study. <i>TH Open</i> , <b>2020</b> , 4, e255-e262	2.7	0
11	Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2280	59.2	0
10	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2772-2780	15.4	0
9	Quality metrics of warfarin initiation in hospitalized older adults. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 459-465	5.1	
8	The HEP-COVID Trial. <i>Heart International</i> , <b>2021</b> , 15, 62	0.3	

7	Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant-Reply. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 333-334	11.5
6	Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. <i>TH Open</i> , <b>2020</b> , 4, e344-e350	2.7
5	Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial. <i>Blood</i> , <b>2014</b> , 124, 4271-4271	2.2
4	External Validation of a Risk Assessment Model for Bleeding Risk in Medical Patients: Findings from the Improve Investigators in a Tertiary Health System. <i>Blood</i> , <b>2015</b> , 126, 748-748	2.2
3	Venous Thromboembolism Prevention in Hospitalized Medical and Surgical Patients <b>2013</b> , 741-745	
2	Using big data to retrospectively validate the COMPASS-CAT risk assessment model: considerations on methodology. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 12-16	5.1
1	Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e025342	6